Sphera Funds Management’s Spyre Therapeutics SYRE Stock Holding History

Sphera Funds Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25,859	Closed	-$187K	–	101
2023 Q1	$187K	Buy	25,859 +8,226	+47%	+$90.2K	0.03%	75
2022 Q4	$198K	Buy	+17,633	New	+$317K	0.04%	57
2019 Q3	–	Sell	-7,488	Closed	-$1.28M	–	99
2019 Q2	$1.28M	Sell	7,488 -31,512	-81%	-$5.45M	0.18%	76
2019 Q1	$7.85M	Buy	39,000 +15,000	+63%	+$3.13M	0.72%	27
2018 Q4	$4.49M	Sell	24,000 -2,124	-8%	-$451K	0.51%	45
2018 Q3	$6.25M	Buy	26,124 +5,759	+28%	+$1.35M	0.72%	34
2018 Q2	$5.39M	Buy	+20,365	New	+$5.01M	0.74%	37

Other funds holding SYRE

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sphera Funds Management's SYRE Position: Q2 2023 in Review

Sphera Funds Management sold out of Spyre Therapeutics (SYRE) in Q2 2023, closing a stake of 25,859 shares — an estimated $187K sold.

Sphera Funds Management first reported a position in SYRE in Q2 2018 and held it in 7 quarters. The position peaked at $7.85M in Q1 2019. 43 funds tracked by Wall St. Rank hold SYRE as of Q2 2023.

Sphera Funds Management reported no remaining Spyre Therapeutics position as of Q2 2023 after selling out during the quarter.
Sphera Funds Management sold 25,859 Spyre Therapeutics shares in Q2 2023, an estimated $187K.
Sphera Funds Management first reported a position in Spyre Therapeutics in Q2 2018 and held it in 7 quarters.
Sphera Funds Management's Spyre Therapeutics position peaked at $7.85M in Q1 2019.
43 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2023.

Based on Sphera Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.